The somatic activating janus kinase 2 mutation (JAK2)^V617F is detectable in most patients with polycythemia vera (PV). Here we report that CP-690550 exerts greater antiproliferative and pro-apoptotic activity against cells harboring JAK2^V617F compared with JAK2^WT. CP-690550 treatment of murine factor-dependent cell Patersen–erythropoietin receptor (FDCP-EpoR) cells harboring human wild-type or V617F JAK2 resulted in inhibition of cell proliferation with a 50% inhibitory concentration...
Continue reading ...